Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas

Expert Opinion on Investigational Drugs
Takashi Watanabe

Abstract

Histone deacetylase inhibitors (HDIs) have been shown effective as single agents for cutaneous T-cell lymphomas, peripheral T-cell lymphomas, and B-cell lymphomas, such as follicular lymphoma and mantle cell lymphoma. Of interest, HDIs in combination with other drugs can be a treatment for Epstein-Barr virus-associated lymphoproliferative disorders. Our data of gene expression profiles in PBMCs of responders to vorinostat was discussed. This review summarizes recent clinical trials of HDIs in non-Hodgkin lymphomas, the effects of HDIs in in vitro and mouse models, and the possibility of future combination treatments. The HDI dosing schedule is crucial to optimize outcomes and avoid irreversible adverse effects. Responses to HDIs are slow, highlighting the need to continue treatment until the maximum response is achieved. HDIs cause hyperacetylation of histone and nonhistone proteins, resulting in various effects on neoplastic cells and immune responses in their microenvironment. Even though HDIs are not potent as single agents, they are likely to provide promising therapeutic options when combined with other agents, i.e., BCL2/BCL-XL antagonists and proteasome inhibitors. Future studies should seek to identify biomarkers that p...Continue Reading

References

Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·S ZollmanF A Laski
Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·A MigliazzaR Dalla-Favera
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
May 10, 2000·Current Biology : CB·A J BannisterT Kouzarides
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Aug 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Jan 5, 2001·Experimental Cell Research·S G Gray, T J Ekström
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E OlsenJ Nichols
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M DuvicUNKNOWN Bexarotene Worldwide Study Group
Feb 28, 2002·Molecular and Cellular Biology·Ari MelnickJonathan D Licht
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
Apr 26, 2002·The Journal of Biological Chemistry·Daniel WolfTony Kouzarides
May 25, 2002·Nature·Charlotte HubbertTso-Pang Yao
Oct 18, 2002·The Journal of Biological Chemistry·Gil BlanderMoshe Oren
Oct 29, 2002·Nature Genetics·Oksana R BereshchenkoRiccardo Dalla-Favera
Apr 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Stephen J HaggartyStuart L Schreiber
Dec 24, 2003·Molecular Cell·K Farid AhmadGilbert G Privé
Dec 30, 2003·Proceedings of the National Academy of Sciences of the United States of America·Constantine S MitsiadesKenneth C Anderson
Mar 17, 2004·Molecular Cell·Haim Y CohenDavid A Sinclair
May 22, 2004·Cell Cycle·Ralph K LindemannRicky W Johnstone
Oct 7, 2004·Journal of the National Cancer Institute·Sameek RoychowdhuryMichael A Caligiuri
Nov 19, 2004·The New England Journal of Medicine·Sandeep S DaveLouis M Staudt
Feb 4, 2005·The New England Journal of Medicine·Mark S KaminskiRichard L Wahl
Mar 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Melissa J PeartRicky W Johnstone
Mar 23, 2005·Archives of Dermatology·Jeanne B BudginAlain H Rook
Apr 21, 2005·The Journal of Clinical Investigation·Ellen J KimAlain H Rook
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kapil N Bhalla
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyVictoria M Richon
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorWilliam K Kelly
Jan 7, 2006·Nature Reviews. Cancer·Saverio Minucci, Pier Giuseppe Pelicci
Apr 1, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Franz TrautingerSean Whittaker
Jun 17, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard L PiekarzSusan E Bates
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Manisha H ShahMichael Grever
Aug 11, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francis GilesKapil Bhalla

❮ Previous
Next ❯

Citations

Mar 19, 2011·Journal of Medicinal Chemistry·Nicholas A Meanwell
Aug 1, 2014·International Journal of Medical Sciences·Sung Hak LeeJinyoung Yoo
Apr 29, 2014·Pharmacology & Therapeutics·Prithviraj BoseSteven Grant
Mar 10, 2016·Expert Opinion on Investigational Drugs·Susmitha Apuri, Lubomir Sokol

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.